基于RenLite的双抗ADC技术平台优势

1. 利用RenLite小鼠产生的全人抗体具有共同的轻链，从而可以有效解决双抗开发过程中的重链和轻链错配的问题，提高组装正确率。

2. RenLite小鼠能够产生表位丰富且亲和力强的抗体。结合KIH（knobs-into-holes）技术连接两个母本单抗的重链，可组装成结构稳定具有单抗结构的双抗分子，保障了后续ADC药物偶联的方便性和成功率。

图1. 基于RenLite平台高通量地产出双抗ADC

3. 依托于百奥赛图“千鼠万抗”计划，以及整合的抗体发现、偶联技术、药理药效平台，我们将对数百个TAA靶点进行高通量抗体发现和筛选，随之对所有潜在双抗ADC组合进行体内外药效筛选，并在自主的大动物转化医学平台进一步验证，获得更具价值的转化数据，提高临床成功率。

图2. 百奥赛图双抗ADC药物开发全流程

百奥赛图双抗ADC研发平台可实现高通量筛选和开发双抗ADC组合，源源不断产生具备高度差异化和创新性的双抗ADC分子。

双抗ADC产品开发

资料下载

AACR 2022：YH012, a Novel Bispecific Anti-HER2 and TROP2 Antibody-Drug Conjugate, Exhibits Potent Antitumor Efficacy  点击下载

World ADC San Diego2022：YH013, a fully-human EGFR x MET bispecific ADC exhibits outstanding specificity and anti-tumor efficacy 点击下载

PEGS EUROPE 2022：YH013, a fully-human EGFR x c-MET bispecific ADC exhibits outstanding specificity and anti-tumor efficacy 点击下载

AACR 2023: A First-In-Class Anti-HER2/TROP2 Bispecific Antibody-Drug Conjugate (YH012) Exhibits Potent Anti-Tumor Efficacy 点击下载

AACR 2023: YH013, a Novel Bispecific EGFR x MET Antibody-Drug Conjugate, Exhibits Potent Anti-Tumor Efficacy 点击下载

AACR 2023: A Novel EGFR x MUC1 Bispecific Antibody-Drug Conjugate, BSA01, Targets MUC1 Transmembrane Cleavage Products and Improves Tumor Selectivity 点击下载

AACR 2023: BCG022: A Novel Bispecific Antibody-Drug Conjugate Targeting HER3 and MET 点击下载

AACR2023：Discovery of BCG033, A Novel Anti-PTK7xTROP2 Bispecific Antibody-Drug Conjugate with Promising Efficacy Against Triple-Negative Breast Cancer 点击下载

AACR 2023: A First-In-Class Anti-TROP2/EGFR Bispecific Antibody-Drug Conjugate, DM001, Exhibits Potent Anti-Tumor Efficacy 点击下载

AACR 2023: A First-In-Class Bispecific Antibody-Drug Conjugate (DM002) Targeting HER3 and the Juxtamembrane Domain of MUC1 点击下载

AACR 2023: Identification of DM004, A First-In-Class Anti-5T4/MET Bispecific Antibody-Drug Conjugate 点击下载